v" The cause of cerebral vasospasm after subarachnoid hemorrhage (SAH) remains unknown. Recently, an association between the potent vasoconstricting peptide, neuropeptide Y, and delayed cerebral vasospasm after SAH has been postulated. This was based on the findings of increased neuropeplide Y levels in the eerebrospinal fluid (CSF) and plasma after SAH in animals and humans. For this study, the primate model of SAH was used to assess the possible role of neuropeptide Y in delayed vasospasm after SAH. Fifteen cynomolgus monkeys underwent placement of a clot of either whole blood or red blood cells in the subarachnoid space around the middle cerebral artery (MCA). Sequential arteriography for assessment of MCA diameter and sampling of blood and CSF for neuropeptide Y were performed: before SAH (Day 0); 7 days after SAH, when signs of delayed cerebral vasospasm peak in this model and in humans; 12 days after SAH; and 28 days after SAH.
F
OR four decades neuroscientists have sought, unsuccessfully, to identify the agent(s) that cause delayed narrowing of cerebral vessels after subarachnoid hemorrhage (SAH). Recently, a new vasoactive peptide was isolated from the porcine brain 65 ' 66 that has been found to be one of the most widely distributed neuropeptides within and without the central nervous system in several species, including manJ '8'9'' ~' 20,22,39.45,47.49,54.57.64,67 This 36-amino acid peptide, named neuropeptide Y after the tyrosine amine at the C terminus and tyrosine residue at the N terminus, is a potent direct and indirect constrictor of peripheral vessels 5'45 and cerebral arteries in rats, ~s,69 cats, 2~ rabbits, 1'19 and man. 3~ Demonstration of neuropeptide Y in the cerebral arteries of rats, 69 cats, 2~ guinea pigs, 7~ and humans, 8 and in the cerebrospinal fluid (CSF) of rabbits 47 and humans '1 suggests its involvement in the regulation of cerebrovascular tone. Increased CSF concentrations of neuropeptide Y in a rabbit model of SAH' and in the CSF of patients with delayed neurological deficit after SAH, 64 depletion of neuropeptide Y activity in arteries of the circle of Willis after SAH in dogs 71 and rats, ~3 and an increase in plasma levels of neuropeptide Y in some patients after SAH, 22 suggest a possible role of neuropeptide Y in the etiology of posthemorrhagic vasospasm.
We used a primate model of SAH and cerebral vasospasm to establish whether changes in the CSF neuropeptide Y concentration are associated with the development of delayed vasospasm after SAH and to determine if there is a correlation between CSF and plasma neuropeptide Y concentrations.
Materials and Methods
The primate model of SAH developed by Weir 
Surgical Procedure
The procedure is generally the same as that described elsewhere. 24 Prior to surgery the monkeys received atropine sulfate (0.05 mg/kg), sodium thiopental (25 mg/ kg), dexamethasone (0.7 mg/kg), cefazolin (500 rng), and intramuscular ketamine (10 mg/kg). They were intubated and ventilated with N20:O2 (1:1), and 0.5% to 1% isoflurane was used as the anesthetic agent. The expired PaCO2 level was maintained at approximately 40 mm Hg by ventilatory control and was confirmed by arterial blood gas level measurements. A right frontotemporal craniotomy was performed under aseptic conditions, the dura mater was opened, and with sharp dissection the sylvian fissure was entered. The arachnoid over the proximal portion of the MCA and internal carotid bifurcation was opened. A clot consisting of 2.5 to 5 ml whole blood or red blood cells in a collagen clot was placed around the right MCA.
Arteriography
To assess vasospasm, cerebral arteriograms were performed 2 to 4 days before surgery and on Days 7 and 12 postoperatively. For arteriography, monkeys were anesthetized with intramuscular ketamine (10 mg/kg) and xylazine (Rompun, 1 mg/kg). A femoral artery cutdown was performed under aseptic conditions and a No. 3 (animals weighing < 5 kg) or No. 4 (animals weighing > 5 kg) French polyethylene catheter was advanced, under fluoroscopic control, to the right internal carotid artery. Contrast medium (0.5 to 0.75 ml Conray 60%) was injected by hand. The filming sequence was 2 films/sec for 3 seconds then 1 film/see for 6 seconds. All filming was carried out with a magnification factor of 2. Subtractions of the anteroposterior projections were made. The presence of vasospasm was defined by comparing the results of cerebral angiography of the right MCA before surgery to the results ofarteriography on Days 7 and 12 after surgery. A computerized image analysis system* was used to measure the area of the proximal 14 mm of the right MCA using an anteroposterior projection (A Zauner, et aL, 
Blood and CSF Sampling
Blood and CSF were sampled on Days 0, 7, 12, and 28. Heparinized blood samples from an arterial line were transferred to tubes with aprotinin (Trasylol, 0.25 mg/ml) and centrifuged at 1200 G for 10 minutes. The plasma was then quickly removed, frozen in dry ice, and stored at -70"C for up to 2 weeks.
Cerebrospinal fluid samples were collected via a percutaneous puncture of the cisterna magna at the time of anesthesia for cerebral arteriography, except the Day 0 samples, which were obtained during surgery through direct access to the CSF cisterns. The CSF was rapidly transferred to tubes with Trasylol (0.25 rag/1 ml CSF), frozen in dry ice, and stored at -70~ for up to 2 weeks.
Neuropeptide Y Radioimmunoassay
After thawing, plasma and CSF samples (2 ml) were extracted with ice-cold acid ethanol (1:2). After 2 hours of incubation at 4"C, the samples were centrifuged for 20 minutes at 2000 G and the supernatants were transferred to prechilled polyethylene tubes and evaporated to dryness in a concentrator. The dry extracts were redissolved in 0.8 ml of ice-cold assay buffer (0.1% Triton X-100, 0.05 M NaC1, 0.5% bovine serum albumin, and 0.01% sodium azide, pH 7.4) and subjected to radioimmunoassay using neuropeptide Y antiserum.t Synthetic porcine neuropeptide Y in serial dilutions of 7.3 to 940 fmol/tube was used to construct a standard curve for the assay. After 24 hours of incubation at 4~ with 100 ul of neuropeptide Y antiserum, [~25I]-radiolabeled synthetic neuropeptide Y was added (6000 cpm at 100 ul/tube) as a tracer, followed by another 24 hours of incubation. Then, 100 ul of goat antirabbit gamma globulin and 100 ul of normal rabbit serum were added to separate free and antibody-bound tracer. After 2 hours of incubation at room temperature, the samples were centrifuged for 20 minutes at 2000 G and the supernatants were discarded. The radioactivity of ['25I]-neuropeptide Y in the remaining pellets was then determined. The assay sensitivity was 15 fmol/tube, the intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 10%. Levels of neuropeptide Y immunoreactivity in plasma and CSF samples are expressed as means _+ standard deviation in pmol/liter.
Statistical Analysis
For statistical analysis the paired and unpaired t-test, analysis of variance (ANOVA), and correlation coefficients were used. Significance was accepted at p < 0.05. (Fig. 1) . When all animals were considered, the differences in neuropeptide Y levels in plasma or CSF on Days 0, 7, 12, and 28 were not significant (ANOVA, p > 0.1).
Correlation of Vasospasm and CSF and Plasma Neuropeptide Y Levels
In animals with vasospasm on Day 7, plasma neuropeptide Y levels were similar to the levels found in monkeys without vasospasm (unpaired t-test, p = 0.76) ( Table 1) . Furthermore, the plasma levels in the group with vasospasm on Day 7 were unchanged from the control levels (paired t-test, p = 0.06), as were the levels in the group without vasospasm (paired t-test, p = 0.78) ( Table 1) .
The CSF levels of neuropeptide Y did not change in association with vasospasm ( Table 1 
Influence of the Clot Type on Neuropeptide Y
Comparison of neuropeptide Y levels in plasma and CSF between the groups of animals with whole blood and red blood cells demonstrated no differences (AN-OVA, p > 0.2). Additionally, there was no significant change in the CSF neuropeptide Y concentrations from basal levels at any sampling time in animals that received either whole blood or red blood cells (ANOVA, p > 0.1).
Correlation of Plasma and CSF Neuropeptide Y in Primates
The neuropeptide Y levels in CSF were almost threefold higher than in plasma in all groups at all times (Table 1 and Fig. 1) . The difference between neuropeptide Y levels in plasma and CSF was highly significant at all sampling times (paired t-test, p < 0.003). Furthermore, there was no correlation of simultaneous values in CSF and plasma, nor was there a correlation between changes in CSF levels and changes in plasma levels (R 2 = 0.014, correlation coefficient 0.117).
Discussion

Neuropeptide Y
The discovery of neuropeptide y,66 the determination of its amino acid structure, 65 its messenger ribonucleic acid isolation from human pheochromoeytoma, and the subsequent synthesis of its complementary deoxyribonucleic acid 52 evoked an intensive search for its physiological role. lmmunohistochemical studies revealed a wide distribution of neuropeptide Y-like im-munoreactivity in the nervous system of mammals. ' 62 and is coreleased with norepinephrine by sympathetic stimuli. 15, 42, 43, 55 The However, certain of the observations purported to link neuropeptide Y and cerebral vasospasm may not be relevant for consideration of delayed cerebral vasospasm after SAH. Although the vasoconstrictive effect of neuropeptide Y was initially observed after intracarotid injection of the neuropeptide, s.~9 peptides exert their action on vessels from an extraluminal, rather than luminal, side of the artery. 6s, 69 The conclusions of neuropeptide Y involvement in cerebral vasospasm by other investigators were based on the observation of increased levels of neuropeptide Y in the CSF rather than in peripheral bloodJ "64 The principal aim of the current study was to clarify the association, if any, of neuropeptide Y in the production of delayed cerebral vasospasm in the primate model of SAH.
Neuropeptide Y Concentration in CSF
The depletion of neuropeptide Y in the arterial wall after SAH 3~' 7~ and the increase in CSF after SAH 1'47'64 suggest neuropeptide Y involvement in delayed vasospasm.I However, in our primate model of SAH, in which nine of 1 5 monkeys developed moderate to severe narrowing of the MCA, there were no changes in the CSF level of neuropeptide Y after SAH and there was no association of the levels of neuropeptide Y in CSF with the presence of vasospasm.
Several factors might account for the differences between our results and those of prior studies. One is the timing of CSF sampling. After SAH, neuropeptide Y is released acutely from MCA storage sites. In the only study that demonstrated higher CSF neuropeptide Y levels after SAH in humans, 64 the increase occurred several days after SAH. The neuropeptide Y increase, however, was related to delayed neurological deficit and not to vasospasm demonstrated by arteriography. However, cerebral ischemia stimulates the central sympathetic nervous system, producing an increase in CSF cateeholamineJ 2,5~,62 Therefore, it is expected that it would also produce an increase in CSF neuropeptide Y levels. Moreover, neuropeptide Y-like immunoreactivity disappears from neocortex and striatum after transient cerebral ischemia, z9 Thus, the delayed neurological deficits produced by cerebral ischemia may have been responsible for the increase in CSF neuropeptide Y concentrations in the patients described by Suzuki, et al. 64 None of the monkeys in our experiment developed delayed neurological deficits that were apparent on daily examination.
It is worthwhile to underline here the difference between the effects of ischemia and SAH on the distri-button of neuropeptide Y storage. Cerebral ischemia does not produce a depletion of neuropeptide Y in cerebral arteries 3s but does deplete neuropeptide Y in cerebral tissue, z9 However, SAH depletes storage of neuropeptide Y in the arterial wall 2L33' 7~ and probably diminishes cerebral storage as well.~'47
Plasma Neuropeptide Y Level
Allen, et al., ~ first discovered that intra-arterial neuropeptide Y decreased CBF in the rat. This was confirmed by Edvinsson, et al., 2~ who related the diminished CBF to potent vasoconstriction of the MCA and of the pial arteries by neuropeptide Y in the plasma. However, Tuor, et at., 68 who repeated Allen's experiment, was unable to confirm the influence of an intracarotid bolus of neuropeptide Y on CBF. They concluded that a peptide that produces prolonged and marked CBF changes must gain access to the abluminal side of the blood-brain barrier. This observation was supported by experiments in vitro, which showed vasoconstriction of the MCA and the pial arteries 2~176 evoked by neuropeptide Y and weak or no vasoconstriction after parenteral infusion.14 '53 In the only report on the plasma level of neuropeptide Y after SAH in humans, Edvinsson, et al., :2 found a correlation between neuropeptide Y levels and vasospasm only in patients with higher blood flow velocity in the MCA, but not for all patients with vasospasm detected by transcranial Doppler ultrasound. Our results, which demonstrate no change in peripheral levels of neuropeptide Y in primates with delayed cerebral vasospasm after SAH, indicate that delayed arteriographically observed vasospasm is not related to changes in plasma neuropeptide Y concentration.
Relationship of CSF vs. Plasma Concentrations of Neuropeptide F
Neuropeptide Y-like activity is detectable in human plasma 6'22'4j and in CSF? TM The neuropeptide Y concentration in plasma rises after stimulation of the sympathetic system. 6'4''4z~4 The level of neuropeptide Y in the CSF is influenced by release of this neuropeptide from the cerebral arterial wall s'18 and/or from the brain in situations (such as cerebral ischemia 29 and SAH 4r) that are known to stimulate potently the sympathetic nervous system? ~'62 In our experiment, there was no correlation between CSF and plasma concentrations of neuropeptide Y, and changes in these concentrations in CSF and plasma were unrelated. This finding suggests that the production and release of neuropeptide Y to CSF and plasma are regulated by different, unrelated, mechanisms.
The significantly higher levels of neuropeptide Y in CSF than in plasma confirm the active release of the peptide to the subarachnoid space from the brain and arteries 47'66 or other unknown sources, ~ but any physiological or pathophysiological role of neuropeptide Y in the CSF remains unclear.
